Open Payments, (more) searchable by anyone

A free tool for searching CMS Open Payments data

Today we launched openpayments.healthcare, a free platform for exploring CMS Open Payments data by company, drug or device brand, or provider.

The CMS Open Payments search tool lets you look up payments by provider, teaching hospital, or company name. It does not support search by drug or device brand name. Our solution, openpayments.healthcare adds brand-name search and lets you see how payments shift across categories and years as products launch and compete.

What the Sunshine Act data covers

CMS Open Payments is the federal transparency program, created under the Physician Payments Sunshine Act, that requires drug and device companies to publicly report what they pay physicians and teaching hospitals: consulting and speaking fees, research funding, royalties, meals, travel, and other transfers of value. CMS has published it every year since 2013, and the running total is now north of $70 billion.

The platform is searchable back to 2022, and you can use it to see where a specific provider has a financial relationship, or watch how spending shifts across a whole category as products launch and patents expire.

One note on the data. Open Payments comes in three buckets: General Payments, Research, and Ownership/Investment. This site is focused on General Payments, since that's what most cleanly reads as a commercial tie to a company through a specific product.  

Drug brand payments and prescription claims growth

We're also publishing an analysis that pairs drug brand-name payments with prescription claims growth, covering 23 drugs across eight therapeutic categories. A few things that stood out:

• Ozempic's payments rose 246% as Novo Nordisk defended its share of the GLP-1 market against astonishing growth from Eli Lily's Zepbound.
• Humira claims fell 62% as biosimilars arrived. AbbVie's payments tied to Humira total just $725K over three years, compared to$111 million for Skyrizi and $53 million for Rinvoq.
• Leqembi prescriptions climbed from roughly 11,000 in 2023 to about 411,000 in 2025, and its payments jumped the year Lilly's Kisunla launched.
• Comirnaty (COVID-19 vaccine) was the highest-spending product of 2025 at over $538 million, though nearly all of that is a single royalty payment to the Hospital of the University of Pennsylvania.

As new products launch and competitors enter, manufacturers change where and how they invest, and that leaves a public trail of where they're placing their bets.

Read the full announcement for additional context on the platform launch.